Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase 3 study. Detailed study ...
UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...
Hosted on MSN1mon
Biogen-UCB's lupus drug meets main goal of late-stage trial(Reuters) - Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after ...
Biogen (NASDAQ:BIIB) and its Belgian partner UCB (OTCPK:UCBJY) announced Tuesday that a Phase 3 trial for an experimental ...
NC 211 is an information and referral service provided by United Way of North Carolina and supported by local United Ways and public and private partners North Carolina leaders mentioned the ...
United Community Banks, Inc. operates as the financial holding company for United Community Bank that provides financial products and services to commercial, retail, government, education ...
We are proud to present, for the first time, the bimekizumab two-year results at EADV 2024," said Fiona du Monceau, Executive Vice President, Head of Patient Evidence, UCB. "These longer-term data ...
United Community Banks, Inc. (NYSE: UCB) (United) today announced net income for the 2024 third quarter of $47.3 million and pre-tax, pre-provision ...
2024 [Test # 2548 - Live] >> 211/5 (45.0 ov, PHKD Mendis 54*, DM de Silva 64*, Shoaib Bashir 0/29) - Stumps Pakistan vs Bangladesh at Rawalpindi, Bangladesh in Pakistan 2nd Test, Aug 30-Sep 3 ...
Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...
ATLANTA, Sept. 27, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE HEARD I and BE HEARD II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback